Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
Keyword(s):
Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.
2002 ◽
Vol 20
(24)
◽
pp. 4628-4635
◽
2021 ◽
Vol 19
(3.5)
◽
pp. BPI21-008
2015 ◽
Vol 16
(7)
◽
pp. 848-858
◽
2014 ◽
Vol 20
(3)
◽
pp. 480-489
◽
2008 ◽
Vol 26
(2)
◽
pp. 264-270
◽
2012 ◽
Vol 30
(15_suppl)
◽
pp. e11017-e11017
2012 ◽
Vol 134
(3)
◽
pp. 1161-1168
◽